Sign-up for our newsletter
MAIN
Event Calendar
Awardee Reports
ABOUT DIACOMP
Citing DiaComp
Contact
Committees
Institutions
Awardee Reports
Publications
Bioinformatics
RESOURCES
Protocols & Methods
Reagents & Resources
Mouse Diet
Breeding Schemes
Validation Criteria
IMPC / KOMP Data
Publications
Bioinformatics
CONTACT
PARTICIPANT AREA
Login
▹
Publications
▹
Home
Publication
Loss of bradykinin signaling does not accelerate the development of cardiac
dysfunction in type 1 diabetic akita mice.
Authors
Wende AR, Soto J, Olsen CD, Pires KM, Schell JC, Larrieu-Lahargue F, Litwin SE,
Kakoki M, Takahashi N, Smithies O, Abel ED
Submitted By
Oliver Smithies on 5/2/2011
Status
Published
Journal
Endocrinology
Year
2010
Date Published
8/1/2010
Volume : Pages
151 : 3536 - 3542
PubMed Reference
20501666
Abstract
Bradykinin signaling has been proposed to play either protective or deleterious
roles in the development of cardiac dysfunction in response to various
pathological stimuli. To further define the role of bradykinin signaling in the
diabetic heart, we examined cardiac function in mice with genetic ablation of
both bradykinin B1 and B2 receptors (B1RB2R(-/-)) in the context of the Akita
model of insulin-deficient type 1 diabetes (Ins2(Akita/+)). In 5-month-old
diabetic and nondiabetic, wild-type and B1RB2R(-/-) mice, in vivo cardiac
contractile function was determined by left-ventricular (LV) catheterization and
echocardiography. Reactive oxygen species levels were measured by
2'-7'-dichlorofluorescein diacetate fluorescence. Mitochondrial function and ATP
synthesis were determined in saponin-permeabilized cardiac fibers. LV systolic
pressure and the peak rate of LV pressure rise and decline were decreased with
diabetes but did not deteriorate further with loss of bradykinin signaling. Wall
thinning and reduced ejection fractions in Akita mouse hearts were partially
attenuated by B1RB2R deficiency, although other parameters of LV function were
unaffected. Loss of bradykinin signaling did not increase fibrosis in
Ins2(Akita/+) diabetic mouse hearts. Mitochondrial dysfunction was not
exacerbated by B1RB2R deficiency, nor was there any additional increase in
tissue levels of reactive oxygen species. Thus, loss of bradykinin B2 receptor
signaling does not abrogate the previously reported beneficial effect of
inhibition of B1 receptor signaling. In conclusion, complete loss of bradykinin
expression does not worsen cardiac function or increase myocardial fibrosis in
diabetes.
Investigators with authorship
Name
Institution
E. Dale Abel
University of Iowa
Oliver Smithies
University of North Carolina
Nobuyuki Takahashi
Tohoku University
Complications
All Complications
Bioinformatics
Bone
Cardiomyopathy
Cardiovascular
Gastro-Intestinal (GI)
Nephropathy
Neuropathy & Neurocognition
Pediatric Endocrinology
Retinopathy
Uropathy
Wound Healing
Welcome to the DiaComp Login / Account Request Page.
Email Address:
Password:
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
click here.
ERROR!
There was a problem with the page:
User Info
User Confirm
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!